The stock of Cyclo Therapeutics Inc (CYTH) has gone down by -25.62% for the week, with a -21.74% drop in the past month and a -30.23% drop in the past quarter. The volatility ratio for the week is 5.70%, and the volatility levels for the past 30 days are 7.84% for CYTH. The simple moving average for the last 20 days is -23.32% for CYTH stock, with a simple moving average of -36.55% for the last 200 days.
Is It Worth Investing in Cyclo Therapeutics Inc (NASDAQ: CYTH) Right Now?
The 36-month beta value for CYTH is also noteworthy at -0.36. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CYTH is 16.64M, and at present, short sellers hold a 1.04% of that float. The average trading volume of CYTH on August 22, 2024 was 56.76K shares.
CYTH) stock’s latest price update
Cyclo Therapeutics Inc (NASDAQ: CYTH)’s stock price has decreased by -28.57 compared to its previous closing price of 1.26. However, the company has seen a -25.62% decrease in its stock price over the last five trading sessions. businesswire.com reported 2024-08-15 that GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2024 and provided a business update. “The second quarter represents a transformative time for the Company with the achievement of a landmark milestone — the.
CYTH Trading at -25.71% from the 50-Day Moving Average
After a stumble in the market that brought CYTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.45% of loss for the given period.
Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 5.70%, as shares sank -19.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.43% lower at present.
During the last 5 trading sessions, CYTH fell by -25.63%, which changed the moving average for the period of 200-days by -10.90% in comparison to the 20-day moving average, which settled at $1.1627. In addition, Cyclo Therapeutics Inc saw -43.40% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CYTH
Current profitability levels for the company are sitting at:
- -18.68 for the present operating margin
- -1.37 for the gross margin
The net margin for Cyclo Therapeutics Inc stands at -18.31. The total capital return value is set at 4.14. Equity return is now at value -22663.91, with -443.08 for asset returns.
Based on Cyclo Therapeutics Inc (CYTH), the company’s capital structure generated -1.41 points at debt to capital in total, while cash flow to debt ratio is standing at -6.13. The debt to equity ratio resting at -0.59. The interest coverage ratio of the stock is -450104.68.
Currently, EBITDA for the company is -20.03 million with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 24.71. The receivables turnover for the company is 13.52for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.45.
Conclusion
In summary, Cyclo Therapeutics Inc (CYTH) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
